CIELO: a randomized, double-blind, placebo-controlled, phase 3 basket study of satralizumab in patients with NMDAR- or LGI1-antibody encephalitis par Gelfand, JM, Abboud, H, Irani, SR, Nakajima, H, Piquet, A, Pittock, SJ, Yeh, EA, Overell, J, Rajan, S, El-Khairi, M, Lee, S-T

Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positi... par Lee, S, Abboud, H, Irani, SR, Nakajima, H, Piquet, AL, Pittock, SJ, Yeh, EA, Wang, J, Rajan, S, Overell, J, Smith, J, St Lambert, J, El-Khairi, M, Gafarova, M, Gelfand, JM

Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis par Arnett, S, Chew, SH, Leitner, U, Hor, JY, Paul, F, Yeaman, MR, Levy, M, Weinshenker, BG, Banwell, BL, Fujihara, K, Abboud, H, Dujmovic Basuroski, I, Arrambide, G, Neubrand, VE, Quan, C, Melamed, E, Palace, J, Sun, J, Asgari, N, Broadley, SA

Specificities of ischemic stroke risk factors in Arab-speaking countries par Abboud, H, Sissani, L, Labreuche, J, Arauz, A, Bousser, M-G, Bryer, A, Chamorro, A, Fisher, M, Ford, I, Fox, KM, Hennerici, MG, Lavados, PM, Massaro, A, Mattle, HP, Collazos, M, Rothwell, PM, Steg, PG, Vicaut, E, Yamouth, B, Amarenco, P

Five-year risk of stroke after TIA or minor ischemic stroke par Amarenco, P, Lavallée, PC, Tavares, L, Labreuche, J, Albers, GW, Abboud, H, Anticoli, S, Audebert, H, Bornstein, NM, Caplan, LR, Correia, M, Donnan, GA, Ferro, JM, Gongora-Rivera, F, Heide, W, Hennerici, MG, Kelly, PJ, Král, M, Lin, H-F, Molina, C, Park, JM, Purroy, F, Rothwell, PM, Segura, T, Školoudík, D, Steg, PG, Touboul, P-J, Uchiyama, S, Vicaut, É, Wang, Y, Wong, LKS